Gilead Sciences, Inc. (GILD) Stock

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is led by CEO Daniel O'Day, employs 17,600 people, headquartered in Foster City, US, publicly traded since 1992.

Gilead Sciences, Inc. (GILD) stock trades at $151.17 with a market capitalization of $187.44B. The stock is valued at a price-to-earnings (P/E) ratio of -58.05, price-to-book of 15.86, price-to-sales of 6.14. Over the past 52 weeks the stock has ranged between $108.46 and $157.29, and currently trades 3.9% below its 52-week high. It pays a dividend yielding 2.17%.

On profitability, Gilead Sciences, Inc. generates a return on equity (ROE) of -16.28%, return on capital employed of -3.89%, an operating margin of 39.74%, a net profit margin of -10.64%.

In its most recent fiscal year, Gilead Sciences, Inc. reported annual revenue of $29.4B, net profit of $8.5B, revenue has compounded at 3.6% a year over the last five years, profit at 133.3% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 2.22 — a leveraged balance sheet worth monitoring, a current ratio of 1.68, total assets of $59.0B, $7.6B in cash and equivalents.

GILD has a beta of 0.35 (less volatile than the overall market).